← Search & browse all drugs
DERMATOLOGICALS › ANTIPSORIATICS › ANTIPSORIATICS FOR SYSTEMIC USE › Other antipsoriatics for systemic use
fumaric acid derivatives, combinations
D05BX51
Forms & Strengths
- Delayed-release oral tablets: Dimethyl fumarate 30 mg / monoethyl fumarate calcium 120 mg
- Delayed-release oral tablets: Dimethyl fumarate 120 mg / monoethyl fumarate calcium/magnesium/zinc 95 mg
Adult Dosing
- Initial: 1 low-strength tablet orally once daily
- Titration: Increase by 1 tablet every week as tolerated
- Maintenance: Up to maximum 3 high-strength tablets daily divided in 3 doses
Pediatric Dosing
- Safety and efficacy not established in pediatric patients under 18 years
Indications
- Treatment of moderate-to-severe plaque psoriasis in adults
Mechanism of Action
- Immunomodulatory and anti-inflammatory effects
- Promotes apoptosis of activated T-lymphocytes
- Induces type II dendritic cell polarization
- Activates nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway
Contraindications
- Hypersensitivity to fumaric acid derivatives
- Severe renal impairment
- Severe hepatic impairment
- Severe gastrointestinal tract disease
- Pregnancy and lactation
Adverse Reactions
- Flushing
- Gastrointestinal complaints (abdominal pain, diarrhea, nausea, flatulence)
- Lymphopenia
- Leukopenia
- Proteinuria
- Elevated liver transaminases
Drug Interactions
- Concomitant systemic immunosuppressive therapies increase risk of severe immunosuppression
- Nephrotoxic drugs may increase risk of renal adverse effects
- Alcohol may increase gastrointestinal intolerance and flushing
Curated Content: Needs Vetting Before Put to Clinical Use